Enhanced calreticulin expression in red cells of polycythemia vera patients harboring the JAK2V617F mutation

Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by increased red cell mass and a high risk of thrombosis, considered as a major cause of mortality and morbidity in this disease. The vast majority of PV patients exhibit the V617F activating mutation in the tyrosine kinase JAK2.[